## **ONCOLOGY** REFERRAL FORM

**PHONE** 888.370.1724 | **FAX** 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMAT	ION									
Last Name	First Name	e DOB		Gender	⊐M □F	Last 4 SSN		Primary Lan	guage	
Address	I		C	City		I			ZIP	
Email Home Phone				Work Phone			Cell Phone			
Primary Contact Method	(check one) 🗌 Cell Pho	ork Phone	Phone							
Primary Caregiver/Alt Contact Name (If applicable) Alt Contact Email Alt Contact Phone										
PRESCRIBER INFOR	MATION									
Name of Contact Sending	Referral	Title			Pref	erred Contact Me	thod (check	one) 🗆 Ema	ail 🗆 Phone 🗆 Fax	
Referral Contact Email		Ļ	Office Phone			Office Fax				
Practice / Facility Name		Prescriber Name / Specialty								
Address				City				State	ZIP	
Prescriber State License # DEA #				NPI #		Medicaid UPIN #				
* Please include a copy of the front and back of insurance card *										
CLINICAL INFORMA	TION - Please inclu	ude applicable clinical	chart no	tes						
Patient New to Therapy  Yes  No, Start Date of Current Therapy: Date Medication Needed										
Treatment History or Failed Therapies (Please also attach recent labs/clinical notes)										
Sample/Starter Provided?  No  Yes, Provide Qty: Date Provided: Patient Height (cm/in): Weight (kg/lbs): Date Obtained:									Obtained:	
Other/Concomitant Medications (please list)										
Allergies  NKDA Drug Allergies (please list)										
Ship to Address										
PRESCRIPTION INFORMATION - Please Escribe if required by state law										
In order for a brand nar	me product to be disp	ensed, the prescriber mus	t handwri	te "Brand Nec						
or your state-specific re	equired language to p	rohibit substitutions. This i	form is no	t a valid presc	ription fc	orm for writing o	controlled i	medications.		
ORAL ONCOLOGY AGENT	rs	1			1				1	
Abiraterone Acetate	Erivedge	Gleevec			Odom	IZO	🗆 Tarceva		□ Votrient	
Afinitor	🗆 Erleada	Gleostine	Leucovorin		□ Onure	g	Targretin		🗆 Xeloda	
Afinitor Disperz	🗆 Erlotinib	Hycamtin	🗆 Leukeran		🗆 Piqray	🗆 Piqray		a 🗆 Xtandi		
□ Alkeran	Etoposide	Hydroxyurea	Mekinist		Rezur	Rezurock			🗆 Xatmep	
🗆 Anastrozole	Everolimus	🗆 Imatinib Mesylate	Mercaptopurine		🗆 Rydapt				🗆 Yonsa	
Arimidex	Everolimus Soluble		Mesnex		□ Scem	Scemblix		ne Citrate	🗆 Zolinza	
🗆 Aromasin	Exemestane	🗆 Jakafi	□ Metho	Methotrexate		🗆 Soltamox			🗆 Zykadia	
🗆 Bexarotene	Fareston	🗆 Kisqali	□ Nilanc	□ Nilandron		Sprycel			🗆 Zytiga	
🗆 Bicalutamide	🗆 Farydak	🗆 Kisqali + Femara Co-Pack	🗆 Niluta	mide	🗆 Sunitinib Malate		Votrient		Other:	
Capecitabine	🗆 Femara	🗆 Lapatinib	🗆 Ninlar	🗆 Ninlaro		🗆 Tabrecta			□ Other:	
🗆 Emcyt	🗆 Gavreto	🗆 Lenvima	🗆 Nolvadex 🛛 🗆 Tafi			ar	🗆 Tykerb		□ Other:	
Dose: Qty: Refills:										
Directions:										
BMS REMS PRODUCTS										
REVLIMID* 2.5 mg	□ 5 mg □ 10 mg □ 1!	5 mg 🗆 20 mg 🗆 25 mg				Risk Category				
Take 1 capsule PO once daily.				0 Refill		ADULT Femal		•	otential	
□ Take 1 capsule PO daily; days 1-21 of 28-day cycle. □ Other:			QTY: 21 QTY:	0 Refill 0 Refill		ADULT Femal     ADULT Male	le, Reproductive Potential			
	□ 100 mg □ 150 mg	□ 200 mg				Female CHILD     Female CHILD			tential	
□ Take 1 capsule PO once daily.			QTY: 28 0 Refills		Male CHILD					
Other:			QTY:			Celgene Auth #				
POMALYST* 1 mg 2 mg 3 mg 4 mg					Date Issued:					
□ Take 1 capsule PO once daily, days 1-21 of 28-day cycle.			QTY: 21			Confirmation #: Date Issued:				
□ Other:			QTY:	0 Refill	5					
Prescriber Signature Date				Supervising	Supervising Physician Signature (where required by state law) Date					
DAW (Dispense as Written) Date				Brand Nece	Brand Necessary (must handwrite)					
DAW (Dispense as Written)		Date legal prescription. Prescriber is to co	moly with his				lines such as o	-prescribing stat	e specific prescription form fax	
		ion form, etc. If more than one page i								
onfidentiality Statement: This me	essage is intended only for the	individual or entity to which it is add	ressed. It may	contain information	which may	be proprietary and co	nfidential. It ma	ay also contain pr	ivileged, confidential informatic	

Which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information. (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.